Investors

Nick Goldner, PhD (YC W19) is a founder, investor, and systems thinker dedicated to building platforms that enhance human potential and resilience—particularly at the intersection of AI, biology, and collective decision-making.

Nick currently serves as Venture Partner @ Alix Ventures, where he supports high potential, early-stage life science startups harnessing the power of biology to drive radical advances in human health. Nick is particularly excited by TechBio founders building platforms that combine Hardware, Software, and Wetware.

Prior to Alix, Nick earned his PhD in Molecular and Cellular Biology at Washington University in St. Louis, where he discovered the molecular drug target of the antibiotic Daptomycin (Cubicin). He later founded Viosera Therapeutics Inc. an antibiotic company focused on creating effective antibiotic combinations using repurposed molecules to to prevent drug resistance. He led the IP strategy that resulted in issued composition of matter patents for combinations of generic drugs in the US, EU, China, and Japan. He later founded resistanceBio Inc. an oncology services company that worked with top 5 Global Pharma and helped other oncology companies design resistance mitigating drug development plans. Nick was also a venture partner at Pioneer Fund focusing on biotech investments.

Nick’s broad research and entrepreneurial experience has given him a unique ability to evaluate technical platforms across all intersection of the clinical development paradigm.

Outside of work, Nicholas explores movement arts (climbing, kiteboarding, swimming), paints abstract expressionist canvases, and writes about evolutionary theory and human systems for Bios.